Elite in Gastroesophageal Reflux Disease (GERD)

Dr. Gary W. Falk

Gastroenterology
3400 Civic Center Blvd, Pcam 4 South, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Gastroesophageal Reflux Disease (GERD)
3400 Civic Center Blvd, Pcam 4 South, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gary Falk is a Gastroenterologist in Philadelphia, Pennsylvania. Dr. Falk is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Reflux Disease (GERD). His top areas of expertise are Barrett Esophagus, Eosinophilic Esophagitis, Esophagitis, Eosinophilic Enteropathy, and Endoscopy.

His clinical research consists of co-authoring 222 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 19 articles and participated in 1 clinical trial in the study of Gastroesophageal Reflux Disease (GERD).

Specialties
Gastroenterology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

3400 Civic Center Blvd, Pcam 4 South, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
Enrollment Status: Recruiting
Publish Date: September 12, 2025
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 2
Study of Compliance, Practice Patterns, and Barriers REgarding Established National Screening Programs for Barrett's Esophagus: SCREEN-BE
Study of Compliance, Practice Patterns, and Barriers REgarding Established National Screening Programs for Barrett's Esophagus: SCREEN-BE
Enrollment Status: Completed
Publish Date: October 22, 2025
Intervention Type: Behavioral
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Application of the Microbiome and Microenvironment to Novel Non-Endoscopic Screening and Surveillance in Barrett's Esophagus
Application of the Microbiome and Microenvironment to Novel Non-Endoscopic Screening and Surveillance in Barrett's Esophagus
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Device
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus
Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus
Enrollment Status: Unknown
Publish Date: August 03, 2022
Intervention Type: Device
Study Phase: Not Applicable
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Enrollment Status: Completed
Publish Date: September 28, 2021
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Enrollment Status: Completed
Publish Date: May 26, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 11 Less Clinical Trials

222 Total Publications

Colibactin-producing E. coli promote carcinogenesis of gastroesophageal adenocarcinoma and simultaneously induce autophagy and differentiation.
Colibactin-producing E. coli promote carcinogenesis of gastroesophageal adenocarcinoma and simultaneously induce autophagy and differentiation.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Similar Doctors
Elite in Gastroesophageal Reflux Disease (GERD)
Dr. Henry P. Parkman
Gastroenterology
Elite in Gastroesophageal Reflux Disease (GERD)
Dr. Henry P. Parkman
Gastroenterology

Temple Digestive Disease Center

3401 N. Broad Street, Ambulatory Care Center, 3rd Floor, 
Philadelphia, PA 
 (4.6 miles away)
800-836-7536
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Parkman is a Gastroenterologist in Philadelphia, Pennsylvania. Dr. Parkman is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Reflux Disease (GERD). His top areas of expertise are Gastroparesis, Gastroesophageal Reflux Disease (GERD), Gastric Dysmotility, Gastrectomy, and Endoscopy. Dr. Parkman is currently accepting new patients.

Elite in Gastroesophageal Reflux Disease (GERD)
Dr. Zubair Malik
Gastroenterology
Elite in Gastroesophageal Reflux Disease (GERD)
Dr. Zubair Malik
Gastroenterology

Virtua Medical Group, PA

90 Brick Rd, Fl 3, 
Marlton, NJ 
 (15.4 miles away)
856-355-6000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zubair Malik is a Gastroenterologist in Marlton, New Jersey. Dr. Malik is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Reflux Disease (GERD). His top areas of expertise are Gastroparesis, Gastroesophageal Reflux Disease (GERD), Barrett Esophagus, Endoscopy, and Gastrectomy.

Distinguished in Gastroesophageal Reflux Disease (GERD)
Dr. Warren Werbitt
Gastroenterology
Distinguished in Gastroesophageal Reflux Disease (GERD)
Dr. Warren Werbitt
Gastroenterology
1939 E Route 70, Suite 250, 
Cherry Hill, NJ 
 (12.7 miles away)
856-429-4433
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Warren Werbitt is a Gastroenterologist in Cherry Hill, New Jersey. Dr. Werbitt is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Reflux Disease (GERD). His top areas of expertise are Esophagitis, Gastroesophageal Reflux Disease (GERD), Tenesmus, and Lower Esophageal Ring. Dr. Werbitt is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Falk's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile